Acorda Therapeutics, Inc. (ACOR)
| Market Cap | 52.39M |
| Revenue (ttm) | 151.90M |
| Net Income (ttm) | -132.02M |
| Shares Out | 9.99M |
| EPS (ttm) | -14.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 111,181 |
| Open | 4.73 |
| Previous Close | 4.66 |
| Day's Range | 4.62 - 4.90 |
| 52-Week Range | 3.27 - 9.84 |
| Beta | 0.58 |
| Analysts | Buy |
| Price Target | 10.00 (+112.3%) |
| Est. Earnings Date | Nov 2, 2021 |
About ACOR
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22...
Financial Performance
In 2020, ACOR's revenue was $152.97 million, a decrease of -20.50% compared to the previous year's $192.41 million. Losses were -$99.59 million, -63.51% less than in 2019.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for ACOR stock is "Buy." The 12-month stock price forecast is 10.00, which is an increase of 112.31% from the latest price.
News
Acorda Therapeutics Announces Corporate Restructuring, Management Changes
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Corporate Restructuring, Management Changes
Acorda Therapeutics (ACOR) Reports Q2 Loss, Tops Revenue Estimates
Acorda (ACOR) delivered earnings and revenue surprises of -9.57% and 6.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Acorda Therapeutics Reports Second Quarter 2021 Financial Results
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Second Quarter 2021 Financial Results
Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021
Will Acorda Therapeutics (ACOR) Report Negative Q2 Earnings? What You Should Know
Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acorda Therapeutics Shares Gains On Spain Distribution Pact For Parkinson's Med
Acorda Therapeutics Inc (NASDAQ: ACOR) has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A. to commercialize Inbrija 33 mg (levodopa inhalation powder, hard capsules) in ...
Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Spain
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Spain
Acorda Therapeutics Announces Repayment of Convertible Senior Notes
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Repayment of Convertible Senior Notes
Acorda Therapeutics (ACOR) Reports Q1 Loss, Tops Revenue Estimates
Acorda (ACOR) delivered earnings and revenue surprises of 3.15% and 30.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Acorda Therapeutics Reports First Quarter 2021 Financial Results
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports First Quarter 2021 Financial Results
Acorda Therapeutics First Quarter 2021 Update: Webcast/Conference Call Scheduled for May 6, 2021
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics First Quarter 2021 Update: Webcast/Conference Call Scheduled for May 6, 2021
All You Need to Know About Acorda (ACOR) Rating Upgrade to Strong Buy
Acorda (ACOR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Celebrity Chef Zarela Martinez Partners with Acorda Therapeutics on the launch of “A Taste for Life with Zarela℠”
ARDSLEY, N.Y.--(BUSINESS WIRE)--Celebrity Chef Zarela Martinez Partners with Acorda Therapeutics on the launch of “A Taste for Life with Zarela”.
Has Acorda Therapeutics (ACOR) Outpaced Other Medical Stocks This Year?
Is (ACOR) Outperforming Other Medical Stocks This Year?
Acorda Therapeutics to Present at H.C. Wainwright Global Life Sciences Virtual Conference
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Present at H.C. Wainwright Global Life Sciences Virtual Conference
Acorda Therapeutics (ACOR) Reports Q4 Loss, Tops Revenue Estimates
Acorda (ACOR) delivered earnings and revenue surprises of -68.92% and 12.24%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021
Acorda Therapeutics (ACOR) Sees Hammer Chart Pattern: Time to Buy?
Acorda Therapeutics (ACOR) has been struggling lately, but the selling pressure may be coming to an end soon.
Acorda Therapeutics Announces Departure of Chief, Business Operations
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Departure of Chief, Business Operations
Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent
Acorda (ACOR) to Report Q4 Earnings: What's in the Cards?
During Acorda's (ACOR) upcoming Q4 earnings call, investor focus will be on the sales uptake of its Parkinson's disease drug, Inbrija.
Acorda (ACOR) Soars on Sale of Manufacturing Unit for Inbrija
Acorda (ACOR) inks an agreement to sell its Inbrija manufacturing operations in Chelsea for $80 million to Catalent. The company also announces a corporate restructuring plan to save costs.
Acorda Therapeutics Announces Agreement for Sale of Manufacturing Operations and Long-Term Global Supply Agreement fo...
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into a definitive agreement to sell its INBRIJA manufacturing operations in Chelsea, Massachu...
Acorda Therapeutics to Present at 39th Annual J.P. Morgan Health Care Conference
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Health Care Co...